| Literature DB >> 35252322 |
Wei Wang1, XiaoShuai Gao1, Liao Peng1, Tao Jin1.
Abstract
BACKGROUND: Ureteroscopy (URS) has been established as an effective treatment for stones in obese patients (OP). However, recent studies found that the efficacy of the procedure may be lower in patients with higher body mass index (BMI). In the current study, we aim to determine if obesity might influence the effectiveness and safety of URS.Entities:
Keywords: meta-analysis; obesity; systematic review; ureteroscopy; urolithiasis
Year: 2022 PMID: 35252322 PMCID: PMC8894321 DOI: 10.3389/fsurg.2022.736641
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1The flow chart showing study search and selection process.
Basic characteristics and data of included articles.
|
|
|
|
|
|
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||||
| Dash et al. ( | USA | Normal-weight | 38 | ND | ND | 27.3 | 11 ± 2 | ND | 23 | 15 | 4-week or greater KUB, IVP or CT | |||
| Morbidly obese | 16 | ND | ND | 44.8 | 13 ± 3 | ND | 6 | 10 | ||||||
| Natalin et al. ( | USA | Normal-weight | 34 | 46.93 | 9:25 | 22.74 (17.82–24.85) | 9 | 19 | 15 | 1 | 31 | 0 to 3 months Post-operatively imaged with CT, and/or IVP | ||
| Overweight | 39 | 51.26 | 20:19 | 27.32 (25.10–29.75) | 8 | 24 | 15 | 0 | 38 | |||||
| Obese | 34 | 53.32 | 21:13 | 33.6 (30.13–45.55) | 8.1 | 19 | 15 | 6 | 28 | |||||
| Best and Nakada ( | USA | Non-obese | 21 | ND | ND | ND | 9.7 | ND | ND | 30-day post-operative imaged with CT, US and KUB | ||||
| Obese | 22 | ND | ND | 32.5 | 8.6 | ND | ND | |||||||
| Delorme et al. ( | France | Non-obese | 149 | 48.2 ± 1.2 | 95:54 | 24 ± 0.2 | 9.35 ± 0.4 | ND | 107 | 29 | 13 | US or CT at 1, 3 and 6 months | ||
| Obese | 29 | 53.5 ± 1.9 | 14:15 | 34 ± 0.6 | 8.38 ± 0.8 | ND | 23 | 3 | 3 | |||||
| Drăgutescu et al. ( | Romania | Normal-weight | 86 | 49 (20–79) | 45:41 | 38.8 (35.2–57.7) | 9 (5–22) | ND | ND | Post-operatively imaged with CT, KUB, and/or IVP | ||||
| Obese | 83 | 47 (22–71) | 39:44 | 22.7 (19.8–24.9) | 8 (4–20) | ND | ND | |||||||
| Caskurlu et al. ( | Turkey | Normal-weight | 81 | 44.4 ± 13.2 | 53:28 | 21.7 ± 1.7 | 18.6 ± 7.1 | 36 | 45 | 75 | 53 | Day 1 and 1 month post-operatively imaged with KUB and US | ||
| Overweight | 77 | 47.8 ± 13.5 | 51:26 | 27.3 ± 0.8 | 16.9 ± 7.0 | 33 | 44 | 64 | 47 | |||||
| Obese | 49 | 46.6 ± 13.2 | 31:18 | 32.8 ± 1.4 | 18.5 ± 8.4 | 23 | 26 | 45 | 36 | |||||
| Chew et al. ( | Canada and USA | Normal-weight | 53 | 52.2 ± 17.9 | ND | 22.4 ± 1.8 | 8.9 ± 0.4 | ND | ND | 3 months post-operatively imaged with CT, KUB, US, and/or IVP | ||||
| Overweight | 76 | 60.9 ± 12.9 | ND | 27.6 ± 1.3 | 7.9 ± 0.4 | ND | ND | |||||||
| Obese | 163 | 52.5 ± 15.4 | ND | 37.1 ± 7.4 | 10.4 ± 1.4 | ND | ND | |||||||
| Pompeo et al. ( | USA | Normal-weight | 82 | 43.8 ± 15.7 | 46:36 | 24.2 ± 3.4 | 9.9 ± 5.0 | ND | 21 | 21 | 40 | post-operatively imaged with CT | ||
| Obese | 60 | 47.1 ± 15.8 | 21:39 | 33.9 ± 2.1 | 10.1 ± 7.6 | ND | 14 | 23 | 23 | |||||
| Morbidly obese | 11 | 44.5 ± 15.1 | 2:9 | 49.0 ± 6.7 | 13.9 ± 6.5 | ND | 4 | 3 | 4 | |||||
| Sari et al. ( | Turkey | Normal-weight | 217 | 40.38 ± 14.3 | 118:99 | ND | 164.1 ± 88.3 | 118 | 96 | 70 | 81 | 6 | 60 | 3 months Post-operatively imaged with CT, KUB and US |
| Overweight | 162 | 42.16 ± 15.2 | 85:77 | ND | 165.8 ± 92.9 | 84 | 74 | 51 | 73 | 3 | 35 | |||
| Obese | 110 | 40.88 ± 15.2 | 48:62 | ND | 185.5 ± 97.9 | 47 63 | 23 | 65 | 0 | 22 | ||||
| Morbidly obese | 13 | 41.54 ± 16.7 | 5:8 | ND | 192.6 ± 85 | 6 7 | 1 | 8 | 0 | 4 | ||||
| Alkan et al. ( | Turkey | Normal-weight | 70 | 39 ± 12 | 45:25 | 22 ± 2 | 10 ± 6 | 28 | 39 | ND | 2 months post-operatively imaged with CT and US | |||
| Overweight | 109 | 41 ± 11 | 88:21 | 27 ± 1 | 9 ± 5 | 39 | 65 | ND | ||||||
| Obese | 77 | 42 ± 13 | 50:27 | 33 ± 2 | 11 ± 8 | 28 | 46 | ND | ||||||
| Morbidly obese | 17 | 43 ± 16 | 12:5 | 44 ± 4 | 11 ± 8 | 5 | 12 | ND | ||||||
| Doizi et al. ( | France | Normal-weight | 188 | 46.6 ± 15.1 | 103:85 | 22.4 ± 2.1 | 15.2 ± 8.7 | 106 | 124 | 74 | 92 | 3 months post-operatively imaged with CT, KUB and US | ||
| Obese | 74 | 53.7 ± 12.6 | 49:25 | 34.3 ± 4.6 | 18.3 ± 13.1 | 45 | 52 | 16 | 33 | |||||
| Morbidly obese | 13 | 51.5 ± 14.1 | 7:6 | 43.5 ± 3.3 | 20.2 ± 13.3 | 9 | 5 | 1 | 7 | |||||
| Doluoglu et al. ( | Turkey | Normal-weight | 29 | 35 (19–84) | 21:8 | 22 (18–24) | 15 (5–36) | 109 | 19 | 17 | 7 | 5 | 1 month post-operatively imaged with KUB and US | |
| Overweight | 49 | 47 (30–76) | 30:19 | 27 (25–29) | 15 (7–35) | 19 | 29 | 23 | 14 | 12 | ||||
| Obese | 28 | 51.5(29–84) | 10:18 | 31 (30–40) | 14.5 (10–28) | 14 | 14 | 12 | 9 | 7 | ||||
| Krambeck et al. ( | USA | Underweight | 250 | 33.69 ± 23.05 | 107:143 | 16.91 ± 1.56 | 55.8 (25.1–117.8) | ND | ND | SFR was determined by post-operative imaging protocols, which differed at each site | ||||
| Normal-weight | 3,574 | 45.91 ± 16.66 | 2,061:1,513 | 22.65 ± 1.68 | 51.8 (23.6–94.2) | ND | ND | |||||||
| Overweight | 4,290 | 50.58 ± 14.55 | 3,037:1,253 | 27.25 ± 1.38 | 56.5 (31.4–103.7) | ND | ND | |||||||
| Obese | 1,758 | 52.56 ± 13.34 | 1,135:623 | 32.99 ± 2.51 | 59.3 (28.3–113.1) | ND | ND | |||||||
| Super obese | 222 | 50.61 ± 12.34 | 91:131 | 45.58 ± 5.80 | 55.0 (19.6–117.8) | ND | ND | |||||||
Using mean (range).
Using mm.
BMI, body mass index; F, female; IVP, intravenous urography; KUB, kidney, ureter, and bladder radiograph; M, male; ND, not documented; SD, standard deviation; SFR, stone-free rate; US, ultrasonography.
Outcome parameters of included studies.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Dash et al. ( | Normal-weight | 84% | ND | ND | 36% |
| Morbidly obese | 67% | ND | ND | 14% | |
| Natalin et al. ( | Normal-weight | 91% | 70.37 (30–170) | ND | ND |
| Overweight | 97% | 88.78 (30–159) | ND | ND | |
| Obese | 94% | 78.23 (30–156) | ND | ND | |
| Best and Nakada ( | Non-obese | 67% | ND | ND | ND |
| Obese | 82% | ND | ND | ND | |
| Delorme et al. ( | Non-obese | 85% | ND | ND | 12% |
| Obese | 85% | ND | ND | 12% | |
| Drăgutescu et al. ( | Normal-weight | 95% | ND | ND | 4.5% |
| Obese | 91% | ND | ND | 6.8% | |
| Caskurlu et al. ( | Normal-weight | 79% | 49.0 ± 14.6 | 1.7 ± 1.6 | 16.0% |
| Overweight | 77.9% | 49.2 ± 14.8 | 1.8 ± 1.8 | 15.6% | |
| Obese | 75.5% | 52.0 ± 10.3 | 1.6 ± 1.7 | 14.3% | |
| Chew et al. ( | Normal-weight | 66% | ND | ND | 13% |
| Overweight | 75% | ND | ND | 9% | |
| Obese | 70% | ND | ND | 6% | |
| Pompeo et al. ( | Normal-weight | 82.9% | 77.5 ± 42.8 | ND | ND |
| Obese | 80% | 66.2 ± 35.1 | ND | ND | |
| Morbidly obese | 90.9% | 85.2 ± 23.4 | ND | ND | |
| Sari et al. ( | Normal-weight | 60.8% | ND | 1.08 ± 1.06 | 16.5% |
| Overweight | 61.7% | ND | 0.95 ± 0.51 | 16.5% | |
| Obese | 73.6% | ND | 1.03 ± 0.77 | 16.3% | |
| Morbidly obese | 61.5% | ND | 1.075 ± 0.61 | 15.4% | |
| Alkan et al. ( | Normal-weight | 81% | 60 ± 24 | 1.08 ± 0.75 | 16% |
| Overweight | 87% | 67 ± 31 | 1.04 ± 0.29 | 13% | |
| Obese | 87.4% | 62 ± 29 | 1 ± 0.375 | 12% | |
| Morbidly obese | 85% | 71 ± 37 | 1 ± 0.33 | 15% | |
| Doizi et al. ( | Normal-weight | 67.4% | 89.8 ± 42.4 | ND | 2.6% |
| Obese | 68% | 72.94 ± 42.1 | ND | 2.1% | |
| Morbidly obese | 71.4% | 77.3 ± 43.6 | ND | 14.3% | |
| Doluoglu et al. ( | Normal-weight | 75.9% | 45.5 (10–100) | 1 (1–1) | 0% |
| Overweight | 89.8% | 50 (30–120) | 1 (1–2) | 6.1% | |
| Obese | 85.7% | 45.5 (25–95) | 1 (1–2) | 7.1% | |
| Krambeck et al. ( | Underweight | 89.2% | ND | ND | 5.6% |
| Normal-weight | 88.1% | ND | ND | 5.0% | |
| Overweight | 87.4% | ND | ND | 5.2% | |
| Obese | 83.1% | ND | ND | 5.3% | |
| Super obese | 73% | ND | ND | 4.9% |
ND, not documented.
Figure 2Forest plot of stone-free rate (SFR). (A) Obese vs. normal-weight. (B) Morbidly obese vs. normal-weight.
Figure 3Forest plot of operation time. (A) Obese vs. normal-weight. (B) Morbidly obese vs. normal-weight.
Figure 4Forest plot of length of stay. (A) Obese vs. normal-weight. (B) Morbidly obese vs. normal-weight.
Figure 5Forest plot of complication rate. (A) Obese vs. normal-weight. (B) Morbidly obese vs. normal-weight.
Figure 6Funnel plot evaluating the publication bias. (A) Stone-free rate. (B) Operation time. (C) Length of stay. (D) Complication rate.